Sitagliptin: an oral agent for glucose control

References

• Bardsley JK, Ratner RE. Pathophysiology of the metabolic disorder. In: The Art and Science of Diabetes Self-Management Education: A Desk Reference for Healthcare Professionals. Mensing C (Ed.). American Association of Diabetes Educators, Chicago, IL, USA 143–157 (2006).
   Google Scholar
• Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American diabetes association and the European Association for the Study of Diabetes. Diabetes Care29, 1963–1972 (2006).
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med.355(23), 2427–2443 (2006).
   PubMed Web of Science ®Google Scholar
• Thornberry NA, Weber AE. Discovery of Januvia (sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of Type 2 diabetes. Curr. Top. Med. Chem.7(6), 557–568 (2007).
   PubMed Web of Science ®Google Scholar
• Karasik A, Ascher P, Katzeff H et al. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with Type 2 diabetes: a review of recent clinical trials. Curr. Med. Res. Opin.24, 489–496 (2008).
   PubMed Web of Science ®Google Scholar
• Green BD, Flatt PR, Bailey CJ. Inhibition of dipeptidylpeptidase IV activity as a therapy of Type 2 diabetes. Expert Opin. Emerg. Drugs11(3), 525–539 (2006).
   PubMedGoogle Scholar
• Bjelke JR, Christensen J, Nielsen PF et al. Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV. Biochem. J.396(2), 391–399 (2006).
   PubMed Web of Science ®Google Scholar
• Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab.80, 952–957 (1995).
   PubMed Web of Science ®Google Scholar
• Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am. J. Physiol.287, E199–E206 (2004).
   PubMed Web of Science ®Google Scholar
• Toft-Nielsen MB, Damholt MB, Madsbad S et al. Determinants of the impaired secretion of glucagon-like peptide-1 in Type 2 diabetic patients. J. Clin. Endocrinol. Metab.86(8), 3717–3723 (2001).
   PubMed Web of Science ®Google Scholar
• Rachman J, Barrow BA, Levy JC, Turner RC. Near normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia40(2), 205–211 (1997).
   PubMed Web of Science ®Google Scholar
• Herman GA, Stevens C, Van Dyck K et al. Pharmacokinetics and pharmacodynamics of single doses of sitagliptin, an inhibitor of dipeptidyl peptidase-IV, in healthy subjects. Clin. Pharm. Therap.78, 675–688 (2005).
   PubMed Web of Science ®Google Scholar
• Deacon CF. Therapeutic strategies based on glucagon-like peptide 1. Diabetes53, 2181–2189 (2004).
   PubMed Web of Science ®Google Scholar
• Inzucchi SE. Oral antihyperglycemic therapy for Type 2 diabetes: scientific review. JAMA287, 360–372 (2002).
   PubMed Web of Science ®Google Scholar
• Ahrén B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with Type 2 diabetes. Diabetes Care27(12), 2874–2880 (2004).
   PubMed Web of Science ®Google Scholar
• Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of Type 2 diabetes. Diabetologia48(4), 616–620 (2005).
   PubMed Web of Science ®Google Scholar
• Mu J, Zhou Y-P, Woods J et al. Direct comparison of efficacy and durability of DPP-4 inhibitor, PPARγ agonist and sulfonylurea on glycemic control and β-cell function in a rodent model of Type 2 diabetes. Presented at: American Diabetes Association 66th Annual Scientific Sessions. Washington, DC, USA, 9–13 June 2006 (Abstract 588-P).
   Google Scholar
• Pospisilik JA, Martin J, Doty T et al. Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes52(3), 741–750 (2003).
   PubMed Web of Science ®Google Scholar
• Lankas GR, Leiting B, Roy RS et al. Dipeptidyl peptidase IV inhibition for the treatment of Type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes54, 2988–2994 (2005).
   PubMed Web of Science ®Google Scholar
• Ahrén B. Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. Expert Opin. Investig. Drugs15(4), 431–442 (2006).
   PubMed Web of Science ®Google Scholar
• Augeri DJ, Robl JA, Betebenner DA et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of Type 2 diabetes. J. Med. Chem.48(15), 5025–5037 (2005).
   PubMed Web of Science ®Google Scholar
• Huettner S, Graefe-Mody U, Ring A, Ritzhaupt A, Dugi KA. BI 1356, a novel and selective xanthine based DPP-IV inhibitor, demonstrates good safety and tolerability with a wide therapeutic window. Presented at: Diabetes Abstract Book, American Diabetes Association 67th Scientific Sessions. Chicago, IL, USA, 22–26 June 2007 (Abstract 586-P).
   Google Scholar
• Forst T, Uhlig-Laske B, Ring A, Ritzhaupt A, Graefe-Mody U, Dugi KA. The novel, potent, and selective DPP-IV inhibitor BI 1356 significantly lowers HbA1c after only 4 weeks of treatment in patients with Type 2 diabetes. Presented at: Abstract Book, American Diabetes Association 67th Scientific Sessions. Chicago, IL, USA, 22–26 June 2007 (Abstract 594-P).
   Google Scholar
• Drucker DJ. The evidence for achieving glycemic control with incretin mimetics. Diabetes Educ.32(Suppl. 2), 72S–81S (2006).
   Google Scholar
• He YL, Sabo R, Campestrini J et al. The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers. Br. J. Clin. Pharmacol.65(3), 338–346 (2007).
   PubMedGoogle Scholar
• Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care29(2), 435–449 (2006).
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetes. Lancet11, 368(9548), 1696–1705 (2006).
   Google Scholar
• Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; for the Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with Type 2 diabetes. Diabetes Care29(12), 2632–2637 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; for the Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with Type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin. Ther.28(10), 1556–1568 (2006).
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with Type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes. Metab.9(2), 194–205 (2007).
   PubMed Web of Science ®Google Scholar
• Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H; for the Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with Type 2 diabetes mellitus. Diabetologia49(11), 2564–2571 (2006).
   PubMed Web of Science ®Google Scholar
• Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with Type 2 diabetes inadequately controlled with metformin alone. Diabetes Care29(12), 2638–2643 (2006).
   PubMed Web of Science ®Google Scholar
• Raz I, Chen Y, Wu M et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with Type 2 diabetes. Curr. Med. Res. Opin.24(2), 537–550 (2008)
   PubMed Web of Science ®Google Scholar
• Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with Type 2 diabetes. Diabetes Obes. Metab.10(10), 959–969 (2008).
   PubMed Web of Science ®Google Scholar
• Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with Type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes. Metab.9(5), 733–745 (2007).
   PubMed Web of Science ®Google Scholar
• Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with Type 2 diabetes. Diabetes Care30(8), 1979–1987 (2007).
   PubMed Web of Science ®Google Scholar
• Herman GA, Bergman A, Stevens C et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab.91(11), 4612–4619 (2006).
   PubMed Web of Science ®Google Scholar
• Herman GA, Stein PP, Thornberry NA, Wagner JA. Dipeptidyl peptidase-4 inhibitors for the treatment of Type 2 diabetes: focus on sitagliptin. Clin. Pharmacol. Ther.81(5), 761–767 (2007).
   PubMed Web of Science ®Google Scholar
• Saisho Y, Maruyama T, Hirose H, Saruta T. Relationship between proinsulin-to-insulin ratio and advanced glycation endproducts in Japanese Type 2 diabetic subjects. Diabetes Res. Clin. Pract.78, 182–188 (2007).
   PubMedGoogle Scholar
• Bergman RN, Finegood DT, Kahn SE. The evolution of β-cell dysfunction and insulin resistance in Type 2 diabetes. Eur. J. Clin. Invest.32(Suppl. 3), 35–45 (2002).
   PubMed Web of Science ®Google Scholar
• Hansen PA, Corbett JA. Incretin hormones and insulin sensitivity. Trends Endocrinol. Metab.16, 135–136 (2005).
   PubMed Web of Science ®Google Scholar
• Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV LAF237 in metformin-treated patients with Type 2 diabetes. Diabetes Care27, 2874–2880 (2004).
   PubMed Web of Science ®Google Scholar
• Herman GA, Bergman A, Yi B, Kipnes M; Sitagliptin Study 012 Group. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with Type 2 diabetes. Curr. Med. Res. Opin.22(10), 1939–1947 (2006).
   PubMed Web of Science ®Google Scholar
• Ruddy MK, Bergman AJ, Zheng W et al. Sitagliptin, a DPP-4 inhibitor, does not inhibit the pharmacokinetics of the sulfonylurea, glyburide. Diabetes55 (Suppl.1), Abstract 558-P (2006).
   Google Scholar
• He YL, Serra D, Wang Y et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with Type 2 diabetes mellitus. Clin. Pharmacokinet.46(7), 577–588 (2007).
   PubMed Web of Science ®Google Scholar
• Mistry GC, Bergman AJ, Luo WL et al. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. J. Clin. Pharmacol.47(2), 159–164 (2007).
   PubMed Web of Science ®Google Scholar
• Bergman AJ, Cote J, Maus A et al. Sitagliptin (MK-0431), a selective dipeptidyl-peptidase-IV (DPP-IV) inhibitor, does not affect the pharmacokinetics of simvastatin in humans. Clin. Pharmacol. Ther.38, Abstract PII-46 (2006).
   Google Scholar
• Miller JL, Migoya E, Talaty JE et al. The effect of MK-0431 on the pharmacokinetics of digoxin after concomitant administration for 10 days in healthy subjects. Clin. Pharmacol. Ther.24, Abstract PI-65 (2006).
   Google Scholar
• Wright D, Maes A, Yi B et al. Multiple dose administration of MK-0431 (sitagliptin), an inhibitor of dipeptidyl peptidase-IV, does not meaningfully alter the plasma pharmacokinetics of pharmacodynamics of single doses of warfarin. Clin. Pharmacol. Ther.76, Abstract PIII-64 (2006).
   Google Scholar
• Migoya EM, Miller J, Larson P et al. Sitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrations. 0286-OR. Diabetes Abstract Book, American Diabetes Association 67th Scientific Sessions. Chicago, IL, USA, 22–26 June 2007.
   Google Scholar
• Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology122, 531–544 (2002).
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ, Creutzfeldt W. Incretins and their analogues as new antidiabetic drugs. Drug News Perspect.16, 413–422 (2003).
   PubMed Web of Science ®Google Scholar